AI could help doctors make better liver cancer decisions
NCT ID NCT07538882
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether an artificial intelligence (AI) model can help doctors more accurately stage and choose treatments for liver cancer (hepatocellular carcinoma). About 108 patients and doctors from different hospitals will participate. Doctors will make decisions with and without AI help to see if the AI improves accuracy and reduces differences between large and small hospitals.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Artificial intelligence (AI) model for staging and treatment decisions
What this could lead to
If successful, this could show that AI helps doctors make more accurate liver cancer staging and treatment decisions, reducing differences in care between large and small hospitals.
What could go wrong
This is a small, early-stage study (108 participants) testing a tool, not a treatment. The AI may not improve accuracy in real-world settings, and results may not apply to all hospitals or patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tsinghua Changgung Hospital
RECRUITINGBeijing, Changping, 102218, China
Contact Phone: •••-•••-•••• Email: •••••@•••••